Astellas Pharma Inc. (ALPMF)
| Previous close | 11.10 |
| Open | 11.00 |
| Bid | 11.35 x 40000 |
| Ask | 12.90 x 40700 |
| Day's range | 11.00 - 11.10 |
| 52-week range | 9.13 - 14.97 |
| Volume | |
| Avg. volume | 2,538 |
| Market cap | 22.475B |
| Beta (5Y monthly) | 0.29 |
| PE ratio (TTM) | 152.62 |
| EPS (TTM) | 0.08 |
| Earnings date | 30 Oct 2024 - 04 Nov 2024 |
| Forward dividend & yield | 0.48 (3.90%) |
| Ex-dividend date | 30 Sept 2024 |
| 1y target est | N/A |
PR NewswireAstellas Unveils New Life Sciences Center in Cambridge, Massachusetts to Accelerate the Discovery of Breakthrough Therapies
Today, Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") officially opened its new Astellas Life Sciences Center (ALSC) in Cambridge, Mass., which will accelerate the company's efforts to create an innovation network across the state, connecting leading incubators, ambitious biotechnology start-ups and academia to foster the discovery and development of potential breakthrough therapies in areas of significant medical need.
PR NewswireAstellas to Present VEOZAH™ (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZAH™ (fezolinetant), its first-in-class treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be featured in four oral presentations during the 2024 Annual Meeting of The Menopause Society (TMS) September 10-14 in Chicago. VMS, also known as hot flashes and/or night sweats, are common symptoms of menopause.1,2
- PR Newswire
European Commission Approves Astellas' PADCEV™ (enfortumab vedotin) in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the European Commission has granted Marketing Authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination with KEYTRUDA® (pembrolizumab, a PD-1 inhibitor) for the first-line treatment of adult patients with unresectable or metastatic urothelial cancer, who are eligible for platinum-containing chemotherapy.
